Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -27.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 95.08 | 44.88 | 44.54 | 12.80 | 18.16 | 22.18 | 38.87 | 62.25 | 106.31 | 1036.64 | 22581.89 | 5333.60 | 2567.85 | 7415.42 | 541.43 | 7008.47 | 4212.49 | 10575.21 | 39859.29 | 1547.74 | 14457.02 |
| — | +102.3% | +14.6% | -79.4% | -82.9% | -97.9% | -99.8% | -98.8% | -95.9% | -86.0% | +4070.8% | -23.9% | -39.0% | -29.9% | -98.6% | +352.8% | -70.9% | +161.0% | +143.9% | -97.5% | +228.4% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.3% | 99.4% | 99.5% | 88.9% | 87.1% | 99.5% | 99.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -1643.9% | -9321.9% | -4963.6% | -16845.7% | -38528.6% | 100.0% | 100.0% |
| — | -0.1% | -0.2% | -11.1% | -12.9% | -0.5% | -0.4% | 0.0% | 0.0% | 0.0% | +106.1% | +101.1% | +102.0% | +100.6% | +95.7% | -9421.9% | -5063.6% | -16945.7% | -38628.6% | +100.9% | 0.0% | |
| Operating Margin | -226.0% | -120.4% | -157.9% | -169.0% | -173.5% | -269.8% | -390.1% | -919.0% | -1314.3% | -9487.4% | -237990.0% | -61430.9% | -97726.8% | -207670.7% | -30994.4% | -115368.5% | -76952.5% | -227491.4% | -685514.3% | -20326.7% | -119448.5% |
| — | +55.4% | +59.5% | +81.6% | +86.8% | +97.2% | +99.8% | +98.5% | +98.7% | +95.4% | -667.8% | +46.8% | -27.0% | +8.7% | +95.5% | -467.6% | +35.6% | -797.7% | -1004.6% | +86.2% | -173.8% | |
| Net Margin | -310.2% | -449.6% | -1431.4% | -161.8% | -209.8% | -350.3% | -784.9% | -783.4% | -1404.0% | -12852.3% | -335272.5% | -167907.9% | -116563.4% | -336290.2% | -32317.5% | -148239.7% | -94015.3% | -270251.4% | -734471.4% | -23399.7% | -132771.2% |
| — | -28.4% | -82.4% | +79.3% | +85.1% | +97.3% | +99.8% | +99.5% | +98.8% | +96.2% | -937.4% | -13.3% | -24.0% | -24.4% | +95.6% | -533.5% | +29.2% | -937.7% | -1182.3% | +84.7% | -205.6% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | -79.4% | -36.1% | -110.2% | -12.1% | -14.6% | -26.2% | -37.8% | -15.8% | -21.2% | -31.8% | -29.6% | -49.8% | -26.4% | -43.5% | -33.0% | -30.3% | -33.1% | -26.7% | -24.0% | -26.7% | -38.0% |
| — | -37.8% | -191.8% | +23.3% | +31.1% | +17.7% | -27.4% | +68.2% | +19.8% | +26.7% | +10.1% | -64.7% | +20.2% | -62.5% | -37.6% | -13.3% | +13.0% | +31.0% | +35.2% | -40.6% | +9.2% | |
| ROIC | -235.9% | — | -30.7% | -39.0% | — | — | — | — | — | — | — | -3209.3% | -46.4% | -46.2% | -53.1% | -31.8% | -29.6% | -22.0% | -27.1% | -38.2% | -65.7% |
| — | — | — | — | — | — | — | — | — | — | — | -10001.1% | -56.6% | -109.8% | -96.0% | +16.8% | +54.9% | +69.5% | +55.7% | -5.4% | +43.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.10 | 5.72 | 6.67 | 5.10 | 5.77 | 4.11 | 2.22 | 3.36 | 2.68 | 3.91 | 3.64 | 5.05 | 2.38 | 0.11 | 0.20 | 0.28 | 2.02 | 0.31 | 0.56 | 0.91 | 1.44 |
| — | +39.2% | +200.5% | +51.8% | +115.5% | +5.1% | -39.1% | -33.4% | +12.4% | +3489.2% | +1712.4% | +1697.8% | +17.9% | -64.4% | -64.0% | -69.0% | +39.9% | -80.0% | -55.3% | -44.7% | -0.1% | |
| Quick Ratio | 5.08 | 5.70 | 6.66 | 5.08 | 5.65 | 3.98 | 2.05 | 3.21 | 2.64 | 3.88 | 3.64 | 5.05 | 2.38 | 0.11 | 0.20 | 0.28 | 1.74 | 0.31 | 0.53 | 0.91 | 1.44 |
| — | +43.2% | +225.3% | +58.4% | +113.7% | +2.5% | -43.8% | -36.4% | +11.0% | +3462.5% | +1712.4% | +1697.8% | +36.9% | -64.4% | -61.8% | -69.0% | +20.5% | -80.0% | -57.9% | -44.7% | -0.1% | |
| Interest Coverage | -2.12 | -11518.50 | -21.23 | -1.28 | -1.44 | -2.20 | -3.50 | -2.97 | -1.13 | -2.45 | -2.73 | -6.27 | -1.73 | -3.29 | -2.94 | -2.79 | -5.63 | -8.73 | -11.01 | -19.39 | -23.47 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IBRX stock.
ImmunityBio, Inc.'s current P/E is -27.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ImmunityBio, Inc.'s current operating margin is -226.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ImmunityBio, Inc.'s business trajectory between earnings reports.